Clinical, biochemical, and endoscopic characteristics within 24 h of admission.
| Case . | Baseline characteristics . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age [years] . | Sex . | Duration of disease [years] . | Extent of disease . | Prior therapies . | FCP [μg/mL] . | CRP [mg/L] . | IUS [Limberg] . | MES [UCEIS] . | Partial Mayo score . | |
| 1 | 22 | F | 3 | E3 | Infliximab, vedolizumab | 936 | 47 | 3 | 2 [6] | 9 |
| 2 | 25 | F | 2 | E3 | Infliximab, vedolizumab | 6000 | 19 | 2 | 3 [6] | 7 |
| 3 | 26 | M | 2 | E3 | Infliximab | 3338 | 39 | 2 | 2 [5] | 7 |
| 4 | 24 | M | 1 | E3 | Infliximab | 2989 | 122 | 2 | 3 [5] | 8 |
| 5 | 58 | M | 38 | E3 | Infliximab, vedolizumab | 1355 | 5 | 3 | 2 [5] | 7 |
| 6 | 41 | M | 5 | E2 | Infliximab, vedolizumab, golimumab | 7000 | 28 | 3 | 3 [6] | 8 |
| Case . | Baseline characteristics . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age [years] . | Sex . | Duration of disease [years] . | Extent of disease . | Prior therapies . | FCP [μg/mL] . | CRP [mg/L] . | IUS [Limberg] . | MES [UCEIS] . | Partial Mayo score . | |
| 1 | 22 | F | 3 | E3 | Infliximab, vedolizumab | 936 | 47 | 3 | 2 [6] | 9 |
| 2 | 25 | F | 2 | E3 | Infliximab, vedolizumab | 6000 | 19 | 2 | 3 [6] | 7 |
| 3 | 26 | M | 2 | E3 | Infliximab | 3338 | 39 | 2 | 2 [5] | 7 |
| 4 | 24 | M | 1 | E3 | Infliximab | 2989 | 122 | 2 | 3 [5] | 8 |
| 5 | 58 | M | 38 | E3 | Infliximab, vedolizumab | 1355 | 5 | 3 | 2 [5] | 7 |
| 6 | 41 | M | 5 | E2 | Infliximab, vedolizumab, golimumab | 7000 | 28 | 3 | 3 [6] | 8 |
MES: Mayo endoscopic score; FCP: faecal calprotectin; CRP: C-reactive protein; IUS: intestinal ultrasound; M: male; F: female, E3: pancolitis, E2: left-sided colitis; UCEIS: ulcerative colitis endoscopic index of severity.
Clinical, biochemical, and endoscopic characteristics within 24 h of admission.
| Case . | Baseline characteristics . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age [years] . | Sex . | Duration of disease [years] . | Extent of disease . | Prior therapies . | FCP [μg/mL] . | CRP [mg/L] . | IUS [Limberg] . | MES [UCEIS] . | Partial Mayo score . | |
| 1 | 22 | F | 3 | E3 | Infliximab, vedolizumab | 936 | 47 | 3 | 2 [6] | 9 |
| 2 | 25 | F | 2 | E3 | Infliximab, vedolizumab | 6000 | 19 | 2 | 3 [6] | 7 |
| 3 | 26 | M | 2 | E3 | Infliximab | 3338 | 39 | 2 | 2 [5] | 7 |
| 4 | 24 | M | 1 | E3 | Infliximab | 2989 | 122 | 2 | 3 [5] | 8 |
| 5 | 58 | M | 38 | E3 | Infliximab, vedolizumab | 1355 | 5 | 3 | 2 [5] | 7 |
| 6 | 41 | M | 5 | E2 | Infliximab, vedolizumab, golimumab | 7000 | 28 | 3 | 3 [6] | 8 |
| Case . | Baseline characteristics . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age [years] . | Sex . | Duration of disease [years] . | Extent of disease . | Prior therapies . | FCP [μg/mL] . | CRP [mg/L] . | IUS [Limberg] . | MES [UCEIS] . | Partial Mayo score . | |
| 1 | 22 | F | 3 | E3 | Infliximab, vedolizumab | 936 | 47 | 3 | 2 [6] | 9 |
| 2 | 25 | F | 2 | E3 | Infliximab, vedolizumab | 6000 | 19 | 2 | 3 [6] | 7 |
| 3 | 26 | M | 2 | E3 | Infliximab | 3338 | 39 | 2 | 2 [5] | 7 |
| 4 | 24 | M | 1 | E3 | Infliximab | 2989 | 122 | 2 | 3 [5] | 8 |
| 5 | 58 | M | 38 | E3 | Infliximab, vedolizumab | 1355 | 5 | 3 | 2 [5] | 7 |
| 6 | 41 | M | 5 | E2 | Infliximab, vedolizumab, golimumab | 7000 | 28 | 3 | 3 [6] | 8 |
MES: Mayo endoscopic score; FCP: faecal calprotectin; CRP: C-reactive protein; IUS: intestinal ultrasound; M: male; F: female, E3: pancolitis, E2: left-sided colitis; UCEIS: ulcerative colitis endoscopic index of severity.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
